India to wait for Covid vaccine as SEC yet to give its nod

New Delhi: India will still have to wait for a Covid vaccine. The Expert Committee is yet to give a nod for use of Serum Institute of India and Bharat Biotech’s vaccines.

The additional data and information presented by SII and Bharat Biotech was perused and analysed by the Subject Expert Committee. The SEC will convene again on 1st January.

The Serum Institute of India which is developing the Oxford Astrazeneca vaccine in India had applied for emergency use authorisation earlier this month but the DCGI had sought more information. The SII’s Adar Poonawalla had on December 28 expressed hope for getting emergency use approval for ‘Covishield’ by the end of this month or January in India.

Experts believe that the AstraZeneca vaccine is more viable for India. Because it can be easily stored and transported making the rollout a swift one.

The  Covishield will cost nearly Rs 500 to Rs 600, making it affordable for many. India might see a coronavirus vaccine rollout in the first week of new year.

Breaking